Immune evasion of Plasmodium falciparum by RIFIN via inhibitory receptors
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Malaria is among the most serious infectious diseases affecting humans, accounting for approximately half a million deaths each year. Plasmodium falciparum causes most life-threatening cases of malaria. Acquired immunity to malaria is inefficient, even after repeated exposure to P. falciparum, but the immune regulatory mechanisms used by P. falciparum remain largely unknown. Here we show that P. falciparum uses immune inhibitory receptors to achieve immune evasion. RIFIN proteins are products of a polymorphic multigene family comprising approximately 150–200 genes per parasite genome that are expressed on the surface of infected erythrocytes. We found that a subset of RIFINs binds to either leucocyte immunoglobulin-like receptor B1 (LILRB1) or leucocyte-associated immunoglobulin-like receptor 1 (LAIR1). LILRB1-binding RIFINs inhibit activation of LILRB1-expressing B cells and natural killer (NK) cells. Furthermore, P. falciparum-infected erythrocytes isolated from patients with severe malaria were more likely to interact with LILRB1 than erythrocytes from patients with non-severe malaria, although an extended study with larger sample sizes is required to confirm this finding. Our results suggest that P. falciparum has acquired multiple RIFINs to evade the host immune system by targeting immune inhibitory receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome sequence of the human malaria parasite Plasmodium falciparum
Gardner, M. J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R. W., Carlton, J. M., Pain, A., Nelson, K. E., Bowman, S., et al. (2002) · Nature · doi:10.1038/nature01097 · Cited by 4,407 · cited 1×
“The P. falciparum genome does not encode an MHC class I-like gene 15 .”
The pathogenic basis of malaria
Miller, L. H., Baruch, D. I., Marsh, K., & Doumbo, O. K. (2002) · Nature · doi:10.1038/415673a · Cited by 1,746 · cited 1×
“PfEMP1 bind endothelial receptors to sequester IEs from blood circulation, allowing parasites to escape splenic clearance 7 .”
Plat-E: an efficient and stable system for transient packaging of retroviruses
Morita, S., Kojima, T., & Kitamura, T. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301206 · Cited by 1,660 · cited 2×
“N-terminal N-terminal conserved and C-terminal variable regions of RIFIN #1 corresponding to amino acid residues 39–139 and 166–275, respectively, were expressed with the transmembrane and cytoplasmic regions of PILR α using the pME18s expression vector, respectively.”
Direct Recognition of Cytomegalovirus by Activating and Inhibitory NK Cell Receptors
Arase, H., Mocarski, E. S., Campbell, A. E., Hill, A. B., & Lanier, L. L. (2002) · Science · doi:10.1126/science.1070884 · Cited by 1,230 · cited 1×
“Next, we investigated whether RIFINs induced LILRB1-or LAIR1-mediated cell signalling using the nuclear factor of activated Tcells (NFAT)-GFP reporter system wherein GFP expression is induced upon ligand interaction with LILRB1 or LAIR1 14,23,24 (Fig.”
Self-citationColonna, M., Navarro, F., Bellón, T., Llano, M., García, P., Samaridis, J., Angman, L., Cella, M., & López-Botet, M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.11.1809 · Cited by 950 · cited 2×
“Natural ligands for LILRB1 are HLA class I molecules 12 .”
Self-citationImmunity to malaria: more questions than answers
Langhorne, J., Ndungu, F. M., Sponaas, A.-M., & Marsh, K. (2008) · Nature Immunology · doi:10.1038/ni.f.205 · Cited by 878 · cited 1×
“In areas with high P. falciparum transmission, immunity to severe malaria is acquired early in life and before acquisition of clinical immunity 2 .”
A Novel Immunoglobulin Superfamily Receptor for Cellular and Viral MHC Class I Molecules
Cosman, D., Fanger, N., Borges, L., Kubin, M., Chin, W., Peterson, L., & Hsu, M.-L. (1997) · Immunity · doi:10.1016/s1074-7613(00)80529-4 · Cited by 695
Severe malaria is associated with parasite binding to endothelial protein C receptor
Turner, L., Lavstsen, T., Berger, S. S., Wang, C. W., Petersen, J. E. V., Avril, M., Brazier, A. J., Freeth, J., Jespersen, J. S., Nielsen, M. A., et al. (2013) · Nature · doi:10.1038/nature12216 · Cited by 559 · cited 1×
“Cerebral malaria and severe anaemia were defined according to a Blantyre coma score 3 and blood haemoglobin 5 g/dl, respectively, as previously described 47 .”
Self-citationAntigenic Variation at the Infected Red Cell Surface in Malaria
Kyes, S., Horrocks, P., & Newbold, C. (2001) · Annual Review of Microbiology · doi:10.1146/annurev.micro.55.1.673 · Cited by 393 · cited 2×
“RIFIN and STEVOR functions are unclear, although single members of these protein families bind uninfected erythrocytes to form so-called rosettes 8 that may facilitate sequestration and evasion of immune recognition in vivo 9 .”
Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia.
Robertson, M. J., Cochran, K., Cameron, C. A., Le, J. M., Tantravahi, R. V., & Ritz, J. (1996) · PubMed · Cited by 343
Cited by
Micsonai, A., Wien, F., Bulyáki, É., Kun, J., Moussong, É., Lee, Y.-H., Goto, Y., Réfrégiers, M., & Kardos, J. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky497 · Cited by 1,131
An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies
Liu, Y., Soh, W. T., Kishikawa, J.-I., Hirose, M., Nakayama, E. E., Li, S., Sasai, M., Suzuki, T., Tada, A., Arakawa, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.032 · Cited by 285
Self-citationLewis Marffy, A. L., & McCarthy, A. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00857 · Cited by 63
“LILRB1 additionally interacts with the UL18 molecules from human cytomegalovirus (HCMV) (51), which is an HLA-I homolog, RIFIN molecules from Plasmodium falciparum (52), Dengue virus through an unidentified ligand (53), and the damage associated molecular pattern proteins S100A8 and S100A9 (54).”
BackgroundSoh, W. T., Liu, Y., Nakayama, E. E., Ono, C., Torii, S., Nakagami, H., Matsuura, Y., Shioda, T., & Arase, H. (2020) · doi:10.1101/2020.11.05.369264 · Cited by 61
Self-citationHuman leukocyte immunoglobulin-like receptors in health and disease
Redondo-García, S., Barritt, C., Papagregoriou, C., Yeboah, M., Frendeus, B., Cragg, M. S., & Roghanian, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1282874 · Cited by 53
“A recent study proposed that LILRB1-binding RIFINs mimic the binding interface of the natural ligands of LILRB1 at the immunological synapse of NK cells, which suppresses NK cell cytotoxicity (96).”
BackgroundLeukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer
Deng, M., Chen, H., Liu, X., Huang, R., He, Y., Yoo, B., Xie, J., John, S., Zhang, N., An, Z., et al. (2021) · Antibody Therapeutics · doi:10.1093/abt/tbab002 · Cited by 53
Blocking LAIR1 signaling in immune cells inhibits tumor development
Xie, J., Gui, X., Deng, M., Chen, H., Chen, Y., Liu, X., Ku, Z., Tan, L., Huang, R., He, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.996026 · Cited by 36
Lee, M. S. J., Inoue, T., Ise, W., Matsuo-Dapaah, J., Wing, J. B., Temizoz, B., Kobiyama, K., Hayashi, T., Patil, A., Sakaguchi, S., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20211336 · Cited by 21
Davies, H., Belda, H., Broncel, M., Dalimot, J., & Treeck, M. (2023) · eLife · doi:10.7554/elife.86367 · Cited by 17
Metadata
- Authors
- Saito, F., Hirayasu, K., Satoh, T., Wang, C. W., Lusingu, J., Arimori, T., Shida, K., Palacpac, N. M. Q., Itagaki, S., Iwanaga, S., Takashima, E., Tsuboi, T., Kohyama, M., Suenaga, T., Colonna, M., Takagi, J., Lavstsen, T., Horii, T., & Arase, H.
- Venue
- Nature
- Published
- 2017-11-29
- Volume
- 552
- Issue
- 7683
- Pages
- 101-105
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2770628073
- Cited by
- 172
- References
- 44
- FWCI
- 14.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.